header logo image


Page 134«..1020..133134135136..140150..»

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

June 8th, 2022 1:52 am

Saint-Herblain (France), June 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th Northern European Conference on Travel Medicine (NECTM8) in Rotterdam.

Read more:
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

Read More...

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the…

June 8th, 2022 1:52 am

PRESS RELEASE

Continue reading here:
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the...

Read More...

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C…

June 8th, 2022 1:52 am

CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors harboring a p53 Y220C mutation demonstrated anti-tumor efficacy across multiple tumor types with an acceptable safety profile. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.

Read more here:
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C...

Read More...

Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

June 8th, 2022 1:52 am

Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022.

Read the original here:
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

Read More...

Halo Pet Launches Multi-Million Dollar Marketing Campaign to Celebrate the World’s Best Kids: Your Pet

June 8th, 2022 1:52 am

New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents

Read this article:
Halo Pet Launches Multi-Million Dollar Marketing Campaign to Celebrate the World's Best Kids: Your Pet

Read More...

Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at…

June 8th, 2022 1:52 am

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be presenting and exhibiting at Outsourcing in Clinical Trials: Medical Devices USA 2022, June 8-9 in Irvine, CA.

Go here to read the rest:
Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at...

Read More...

Inventiva joins the Euronext Tech Leaders segment

June 8th, 2022 1:52 am

Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it will join the Euronext Tech Leaders initiative, a new Euronext segment comprised of more than 100 high-growth and leading Tech companies across Europe.

View original post here:
Inventiva joins the Euronext Tech Leaders segment

Read More...

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

June 8th, 2022 1:52 am

BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

Visit link:
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Read More...

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

June 8th, 2022 1:52 am

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Excerpt from:
Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Read More...

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 8th, 2022 1:52 am

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

See more here:
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Read More...

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

June 8th, 2022 1:52 am

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT.

Read more:
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

Read More...

Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

June 8th, 2022 1:52 am

SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.

Go here to read the rest:
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

Read More...

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

June 8th, 2022 1:52 am

Montrouge, France, June 7, 2022

Read more here:
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Read More...

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic…

June 8th, 2022 1:52 am

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Original post:
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic...

Read More...

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

June 8th, 2022 1:52 am

Orphazyme A/SCompany announcementNo. 30/2022                                                                        Annual reportwww.orphazyme.com Company Registration No. 32266355

Read the original:
Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Read More...

Notice to convene Annual General Meeting

June 8th, 2022 1:52 am

Orphazyme A/SCompany announcementNo. 31/2022www.orphazyme.comCompany Registration No. 32266355

See the rest here:
Notice to convene Annual General Meeting

Read More...

European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

June 8th, 2022 1:52 am

Basel, 8 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio® (mosunetuzumab), for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment.

Read more here:
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

Read More...

Addressing the ‘Trust Factor’: South Carolina Researchers Tackle Health Disparities Using Genetics – Physician’s Weekly

June 8th, 2022 1:50 am

Quenton Tompkins family tree is deeply rooted in rural McCormick County, South Carolina.

His grandfather was a sharecropper in McCormick. His mother, who turns 88 this month, grew up as the youngest of 24 children. Branches of aunts, uncles, and cousins now stretch from Florida to Chicago.

And although 48-year-old Tompkins has heard plenty of stories, his family holds its secrets, too.

He didnt know until he was an adult that his grandfather died of leukemia. And hes still unsure if his fathers bout with prostate cancer runs in the family. Tompkins mother and her siblings have dealt with a range of health issues, including diabetes, heart attacks, and strokes, but he still doesnt know what killed his grandmother more than 70 years ago.

Those are questions I go through personally, said Tompkins, a lobbyist for the Medical University of South Carolina. Theres another side to knowing where you come from.

Twenty-two years ago, President Bill Clinton announced the completion of a draft version of the Human Genome Project, a breakthrough he described as the language in which God created life. He predicted that scientists, armed with genetic discoveries, would find cures for Alzheimers disease, cancer, Parkinsons disease, and diabetes in the coming years.

Clintons prediction, of course, hasnt yet come to pass. But researchers in Charleston are hopeful that a large genetics research project underway across South Carolina may help scientists address some of the states persistent health disparities, which disproportionately impact its Black residents and regularly rank among the nations worst.

The university health system intends to enroll 100,000 of South Carolinas 5 million residents in genetic testing over the next four years in hopes of better understanding how DNA influences health. Researchers also want to recruit participants who reflect the diversity of the states population.

Its an ambitious goal. With nearly 27% of South Carolina residents identifying as Black or African American, the MUSC genetics research project, called In Our DNA SC, would if successful accomplish something most other genetics research projects have failed to do. Historically, diverse participation in this type of research has been very low.

Theres a trust factor. Its plain and simple, said Tompkins, who is developing an outreach program for the project.

He referenced Henrietta Lacks, a Black woman in Baltimore whose cells were used without her or her familys knowledge for research purposes by doctors at Johns Hopkins University in the 1950s, and the Tuskegee syphilis study, conducted over nearly 40 years starting in the 1930s. Researchers deceived hundreds of Black men enrolled in the study, telling them they were being treated for syphilis when, in fact, they were left untreated, even after penicillin became widely available.

Those are still fresh in many peoples minds, Tompkins said. Weve come a long way from those stories it doesnt dismiss what happened but there are a lot more controls and oversight in place to ward those things off from happening again.

But its not only history feeding this distrust. Bias and racism evident in medicine today contribute to the problem.

Diversity in genetics research is so low that approximately 90% of participants in projects launched since the first sequencing of the human genome have been individuals of European descent or those who identify as white, said Dr. Shoa Clarke, a pediatric cardiologist and geneticist at Stanford University.

These numbers affect real-life health care. Clarke and others published research last year showing that a DNA-based tool used to assess a patients risk of developing high cholesterol works reliably well only when administered to those of Northern European descent. Thats because the tool was developed using information from genetic bio-banks largely made up of DNA from white people. And aside from a large DNA bank compiled by the Department of Veterans Affairs, this is generally the norm.

Human beings, regardless of race, are more than 99% genetically identical, but small variations and mutations passed down through generations can influence health outcomes in huge ways, Clarke explained.

Genetics is not the cause of health disparities, he said. But as we move toward using genetics in clinical settings, its very possible they could create new disparities.

In South Carolina, health disparities between Black and white patients are already acute, said Marvella Ford, a researcher at MUSCs Hollings Cancer Center in Charleston.

South Carolina compared to the rest of the country were usually in the bottom tier, Ford said. The prostate cancer mortality rate in South Carolina, for example, is 2 times higher for Black men than white men, she said.

When you look at most other chronic conditions, she said, you see the same thing.

She called the genetics project at MUSC a great opportunity to open the doors. Even so, the topic of recruiting Black research participants for genetics studies is complex.

Theres debate on how we should be doing this work, said Shawneequa Callier, an attorney and an associate professor of bioethics at George Washington University. Theres just so much diversity in Africa. Its the cradle of humanity.

Men and women transported to Charleston and other American port cities during the transatlantic slave trade came from a wide region of Africa mostly from West Central Africa, but in large numbers from regions farther north, too. Once in America, they were often separated and forced hundreds of miles apart. This explains why someone whose ancestors lived on one of South Carolinas barrier islands may have inherited different genetic variants than someone from a multigenerational Black family inland in McCormick County, just north of Augusta, Georgia.

Thats also why categorizing genetics research participants simply as Black or African American, without more context, may not yield particularly useful research insights, Callier said.

If you dont study the data and study it well, thats a real dereliction of ethical duty, Callier said.

Those who choose to participate in the MUSC project stand to benefit from it directly, its organizers said. After submitting a saliva sample, each participant will receive a report indicating if they have one or more of three genetic conditions that may put them at a higher risk for heart disease and certain cancers such as one of the BRCA mutations linked to breast cancer. If they test positive for one of these conditions, they will be connected at no cost to a genetics counselor, who can assist with information and treatment options related to a patients inherited risks. Participants will also learn where their ancestors likely lived.

The de-identified DNA data will then be used by researchers at MUSC, as well as those at Helix, a private California-based genomics company, which will process the saliva samples and extract the genetic information from each participants sample. Researchers at MUSC and Helix have indicated they hope to use the results to better figure out how DNA affects population health. Heather Woolwine, an MUSC spokesperson, said the project will cost $15 million, some of which will be paid to Helix. Hospital revenue will fund the research, she said.

Tompkins expects to receive a lot of questions about how it all will work. But hes used to questions. He said he encountered much of the same hesitancy when he helped set up MUSC covid testing and vaccine sites across the state. Many people regardless of race worried microchips or tracking technology had been embedded into the covid vaccines, he said.

Tompkins found that the key to persuading residents in rural parts of the state to consider the covid vaccine was to seek out invitations from trusted, local leaders, then set up events with them. South Carolinas covid vaccination rate remains lower than the national average, but Tompkins said some skeptics have been more receptive to MUSCs message because the hospital system has focused on building relationships with organizers outside Charleston. He hopes to use those relationships to spread word about the new genetics research project.

You have to build those relationships and find community champions that can help you open doors and gather people, he said. Then, its about letting them choose.

By Lauren SausserKaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation, which is not affiliated with Kaiser Permanente.

Read the original here:
Addressing the 'Trust Factor': South Carolina Researchers Tackle Health Disparities Using Genetics - Physician's Weekly

Read More...

Dumb luck, genetics? Why have some people never caught COVID-19? | Daily Sabah – Daily Sabah

June 8th, 2022 1:50 am

It has been more than two years since the start of the global COVID-19 pandemic. Throughout that time, for some people, the infections became more frequent and hit closer to home. Their friends contracted coronavirus, and sometimes their children, grandparents and most of their co-workers too. It seemed to be only a matter of time before they would contract the virus as well but their luck never ran out it seems as if some people have never been knowingly infected with COVID-19 in over two years even after the wave of infections caused by the highly transmissible omicron variant.

If you ask them the reason, you'll hear all sorts of suppositions. For example, regular long trips on the underground will build up your resistance by repeatedly exposing you to small viral loads.

"This hypothesis falls in the realm of speculation," says Dr. Ulf Dittmer, director of the Institute of Virology at Essen University Hospital in Germany.

Some people not previously infected attribute it to scrupulously following COVID-19 precautions. Others thank their lucky stars for not contracting the virus from a contact person who later tested positive or while they partied at a club. Still, others wonder if they had an asymptomatic infection that wasn't detected, for instance before testing was widely available. Or maybe they did have symptoms but tested negative because the sample was collected improperly or the timing was inopportune.

Scientific attempts at an explanation go deeper, but there's no single definitive answer as to why some people still haven't caught COVID-19. A combination of factors could be the reason.

"A number of hypotheses appear plausible," says Dr. Leif Erik Sander, director of the Department of Infectious Diseases and Respiratory Medicine at Charit University Hospital in Berlin.

First of all, it's important to bear in mind that a significant number of COVID-19 infections go largely or completely unnoticed. In a systematic review and meta-analysis published late last year in the Journal of the American Medical Association (JAMA) Network Open, the authors noted that about 40% of people with a confirmed COVID-19 diagnosis were asymptomatic at the time of the test. The finding was based on 95 international studies involving nearly 30 million people.

The frequency of testing obviously plays a role in detecting infections. If you're not tested regularly, there's a greater chance you won't become aware of a mild or asymptomatic infection.

And your genes can play a role too in whether or not you get COVID-19.

"There are people who, owing to genetic characteristics, can't easily be infected with malaria or HIV (the virus that causes AIDS), for instance. In certain gradations this will also be true of Sars-CoV-2," says Sander, adding that the genetic factors aren't completely understood, however.

As virologist Dittmer explains, human leukocyte antigens (HLA) molecules, which are encoded by a complex of genes, play an important part in the body's immune response to pathogens such as Sars-CoV-2. He adds that a person's blood group, too, not only influences disease severity but perhaps also susceptibility to infection with the virus.

The protection provided by vaccinations is probably often underestimated. Although levels of antibodies in your blood able to bind to and neutralize invading coronaviruses decline some time after injection with a vaccine, "protection nevertheless remains significant for months," Sander says. "That, too, reduces infections."

Immune responses to COVID-19 vaccines vary from person to person. "If the response is especially good, vaccination in combination with a previous infection with one of the four endemic common cold coronaviruses can also play a role," he suggests.

According to Dittmer, a particular subclass of antibodies has been found to provide especially good protection from a novel coronavirus infection. "Measuring them is complicated though, so for the time being no one will know whether they've got these antibodies or not," he says.

The fact that children who get COVID-19 tend to have either no or only mild symptoms is down to their generally having an innate immune response that's stronger than the immune response of adults, according to Sander. It's often "preactivated," so to say.

Another phenomenon worth mentioning is that for a few days after getting an infection, people are typically less susceptible to infection with another pathogen. "This is due in part to interferons, which are defensive proteins in mucous membranes that also reduce susceptibility to Sars-CoV-2 in the event of contact with it in that time window," Sander says.

He also notes that some people's immune system may rid their body of the virus very quickly: "In a Swedish study, researchers detected specific T-cells (a type of white blood cell that's part of the immune system) in people who didn't test positive after contact with infected household members a sign their immune system had indeed engaged Sars-CoV-2 even though an infection or antibodies against the virus weren't always detectable."

So what are we to conclude? If you think you've somehow managed to skirt a COVID-19 infection, you may already have one behind you. Or you may have benefited from certain temporary circumstances, as-yet-unexplained genetic factors and/or dumb luck.

"Just because you haven't had COVID-19 yet doesn't mean you're permanently safe," Sander warns. "A new coronavirus variant, or a different set of circumstances, can totally change that."

The Daily Sabah Newsletter

Keep up to date with whats happening in Turkey, its region and the world.

SIGN ME UP

You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Read the rest here:
Dumb luck, genetics? Why have some people never caught COVID-19? | Daily Sabah - Daily Sabah

Read More...

Genetics Breakthrough in Sea Urchins to Aid in Biomedical Research – Scripps Institution of Oceanography

June 8th, 2022 1:50 am

Marine biologists at Scripps Institution of Oceanography at UC San Diego have created a line of sea urchins whose genetic makeup is fully mapped and can be edited to study human disease genes. The creation of these new research model organisms will accelerate the pace of marine biomedical research.

Sea urchins, like fruit flies or lab rats, have been an organism used in research for more than a century. Even before this breakthrough, sea urchins led to the discovery of a protein family known as cyclins that guides division of cells. That knowledge went on to become the basis of current cancer treatments and earned cyclins discoverers a Nobel Prize.

Now Scripps marine biologist Amro Hamdoun and colleagues have taken this research to a new level by developing lines of sea urchins that can be used as genetic models using the gene editing technology known as CRISPR. The modified sea urchins are derived from the fast-growing species, Lytechinus pictus, also known as the painted sea urchin.

The team describes its results June 6 in the journal Development.

Hamdoun said the new sea urchins could serve as a new workhorse organism in marine biomedical research, capable of being cultivated to adulthood in four to six months at room temperature. Presently many species of sea urchins are used around the world to study the developmental origins of diseases, and the effects of pollutants on human and marine health. But few can be grown in the lab and genetically modified like other lab animals. Having this new genetically enabled urchin could dramatically enhance the efficiency, reproducibility, and utility of those studies.

Sea urchins have long been a favorite model organism for marine biologists, but they have been bottlenecked by not having stable genetics, Hamdoun said. This work breaks that final barrier. This genetically enabled urchin will be an important resource for the large community of researchers who use urchins in their labs.

The research was an unexpected silver lining from the COVID pandemic which impacted operations in research labs around the country for more than two years. In the case of Hamdouns lab, team members developed a sense of mission that motivated them to continue with the work.

It gave us something positive to focus on, Hamdoun said. The team spent two years intently focused on solving the barriers to making a genetically enabled sea urchin. Once we figured out how to make the precise modifications we wanted, we next had to figure out how to efficiently culture the urchins and select the modified animals. It is a real testament to the groups dedication that they accomplished this despite the adverse circumstances. I like to think that while many people were home growing cool things like houseplants or sourdough starters, we were also growing something interesting, but it was a biomedical research animal.

Besides Hamdoun, co-authors of the study included Himanshu Vyas, Jose Espinoza, Catherine Schrankel, Kasey Mitchell, Katherine Nesbit, Elliot Jackson, Nathan Chang, Yoon Lee, and Deirdre Lyons of Scripps Oceanography as well as researchers from University of North Carolina Charlotte and Wilmington campuses.

The National Institutes of Health Program on Oceans and Human Health and the National Science Foundation funded the research.

Read more:
Genetics Breakthrough in Sea Urchins to Aid in Biomedical Research - Scripps Institution of Oceanography

Read More...

Page 134«..1020..133134135136..140150..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick